

## Topics

The symposium deals with the development of non-carrier-based targeted tumor therapies and their clinical application, with special focus on target recognition, drug design and production, and innovative strategies for improvement.

Topics and Main Speakers	
<b>Generation and design of chimeric toxins</b>	
<i>Christopher Bachran</i> (Berlin, Germany)	<i>Michael G. Rosenblum</i> (Houston, TX, USA)
<i>Marco Colombatti</i> (Verona, Italy)	<i>Mehmet K. Tur</i> (Aachen, Germany)
<i>Ursula Elsässer-Beile</i> (Freiburg, Germany)	<i>Daniel Vallera</i> (Minneapolis, MN, USA)
<i>Stephen H. Leppla</i> (Bethesda, MD, USA)	<i>Winfried S. Wels</i> (Frankfurt/M., Germany)
<b>Directed enzyme prodrug therapy</b>	
<i>Kenneth D. Bagshawe</i> (London, UK)	<i>P. Markus Deckert</i> (Brandenburg, Germany)
<i>Kerry Chester</i> (London, UK)	
<b>Targeted RNases</b>	
<i>Claudia De Lorenzo</i> (Naples, Italy)	<i>Susanna M. Rybak</i> (Green Cove Springs, FL, USA)
<i>Thomas Schirrmann</i> (Braunschweig, Germany)	<i>Kuslima Shogen</i> (Somerset, NJ, USA)
<i>Jürgen Krauss</i> (Heidelberg, Germany)	
<b>Innovative tools to improve targeted tumor therapies</b>	
<i>Stefan Barth</i> (Aachen, Germany)	<i>Masanori Onda</i> (Bethesda, MD, USA)
<i>Hans Bäumlér</i> (Berlin, Germany)	<i>Ansgar Santel</i> (Berlin, Germany)
<i>Hendrik Fuchs</i> (Berlin, Germany)	<i>Mark Sutherland</i> (Bradford, UK)
<i>Walter A. Hall</i> (Syracuse, NY, USA)	<i>Andrew Thorburn</i> (Denver, CO, USA)
<i>Wijnand Helfrich</i> (Groningen, Netherlands)	
<b>Targeted tumor therapies in clinical applications</b>	
<i>Horst Dürkop</i> (Berlin, Germany)	<i>Elke Pogge von Strandmann</i> (Köln, Germany)
<i>Arthur E. Frankel</i> (Temple, TX, USA)	

## Program

Wednesday 01 April 2009	
<b>Morning</b>	
09:00	Registration and placing of posters
10:30	Welcome ( <i>Christopher Bachran</i> )
10:45	<b>Christopher Bachran</b> (Berlin, Germany) Opening talk: Targeted therapy — past, present, and future <i>Chair: Christopher Bachran</i>
11:15	<b>Luzie Fabisch Memorial Lecture</b> <b>Arthur E. Frankel</b> (Temple, TX, USA) Recombinant toxin therapy of leukemia
12:00	<b>Daniel Vallera</b> (Minneapolis, MN, USA) Genetic design of new bispecific fusion toxins for carcinoma therapy
12:35	<b>Dafne L. Müller</b> (Stuttgart, Germany) Bispecific and bifunctional antibody molecules for targeted cancer immunotherapy
12:55	<b>Serena Fabbrini</b> (Milan, Italy) <i>Pichia pastoris</i> as a host for secretion of saporin-based chimeras with anti-cancer potential
13:15	Coffee, snack & posters
<b>Wednesday 01 April 2009</b>	
<b>Afternoon</b>	
<i>Chair: Stefan Barth</i>	
15:00	<b>Ursula Elsässer-Beile</b> (Freiburg, Germany) New targeted therapies against prostate cancer with PSMA-specific immunotoxins and diabodies
15:35	<b>Marco Colombatti</b> (Verona, Italy) Immunotoxins to prostate tumors
16:10	<b>Mehmet K. Tur</b> (Aachen, Germany) Immunokinases, a novel class of immunotherapeutics for targeted cancer treatment
16:45	<b>Winfried S. Wels</b> (Frankfurt am Main, Germany) Targeted induction of apoptosis by immunotoxin-like fusion proteins employing human effector functions
17:20	Coffee break <i>Chair: Michael G. Rosenblum</i>
17:45	<b>Hans Bäumlér</b> (Berlin, Germany) Red blood cells as carriers for targeted drug delivery to tumor cells
18:20	<b>Andrew Thorburn</b> (Aurora, CO, USA) Manipulation of other processes to improve the effectiveness of tumor-targeted toxins
18:55	<b>Mark Sutherland</b> (Bradford, UK) Cytochrome P450 specific activation of prodrug ultrapotent chemotherapeutics
19:30	Get together & posters
after it	Free time to explore Berlin by night

Thursday 02 April 2009	
Morning	
<i>Chair: Kuslima Shogen</i>	
08:30	<b>Walter A. Hall</b> (Syracuse, NY, USA) Convection enhanced delivery: Neurosurgical issues
09:15	<b>Kuslima Shogen</b> (Somerset, NJ, USA) ONCONASE as a cancer drug and targeted payload
09:50	<b>Susanna Rybak</b> (Green Cove Springs, FL, USA) Integrating extracellular and intracellular specificity
10:25	Coffee break
10:50	<b>Jürgen Krauss</b> (Heidelberg, Germany) Development of immunoRNases for treatment of CD22+ malignancies
11:25	<b>Thomas Schirrmann</b> (Braunschweig, Germany) Human RNase fusion protein targeting CD30+ tumors
12:00	<b>Claudia De Lorenzo</b> (Naples, Italy) Novel human anti-ErbB2 immunoagents
<i>Chair: Hendrik Fuchs</i>	
12:35	<b>Matthias Maak</b> (München, Germany) Tumor targeting of colorectal carcinoma and liver metastasis with Shiga toxin B
12:50	<b>Güliz Parmaksiz</b> (Berlin, Germany) <i>In vivo</i> biodistribution and microvascular binding of a high-affinity monoclonal antibody fragment F8-SIP against the extra-domain A of fibronectin
13:05	<b>Marcelo Calderon</b> (Berlin, Germany) Development of macromolecular prodrugs derived from dendritic polyglycerol
13:20	Lunch & posters

Thursday 02 April 2009	
Afternoon	
<i>Chair: Nicole Schellmann</i>	
14:30	<b>Kenneth D. Bagshawe</b> (London, UK) Antibody-directed enzyme prodrug therapy (ADEPT)
15:15	<b>P. Markus Deckert</b> (Brandenburg & Berlin, Germany) Recombinant fusion proteins for targeted enzyme prodrug therapy in colon and pancreatic cancer
15:50	<b>Kerry Chester</b> (London, UK) Bench to bedside with recombinant antibody-based cancer therapeutics
16:25	Mini refreshment
16:50	Bus transfer to the Spree
17:30	Boat tour including dinner
21:30	Bus transfer to the hotels

Friday 03 April 2009	
Morning	
<i>Chair: Marco Colombatti</i>	
08:30	<b>Masanori Onda</b> (Bethesda, MD, USA) Strategy to reduce immunogenicity of <i>Pseudomonas</i> exotoxin based immunotoxin
09:15	<b>Stefan Barth</b> (Aachen, Germany) Novel immunotherapeutics for treatment of human diseases
09:50	<b>Ansgar Santel</b> (Berlin, Germany) AtuPLEX a novel RNAi-based delivery system for cancer therapies
10:25	Coffee break
<i>Chair: Stephen H. Leppla</i>	
10:50	<b>Hendrik Fuchs</b> (Berlin, Germany) Saponins as tool for drastically improved targeted tumor therapy
11:25	<b>Wijnand Helfrich</b> (Groningen, The Netherlands) Targeting molecules of "life and death" for cancer therapy
12:00	<b>Elke Pogge von Strandmann</b> (Köln, Germany) NK cell-based immunotherapy of lymphoid malignancies
12:35	<b>Yvonne Andersson</b> (Oslo, Norway) The combination of immunotoxins and the immunosuppressor cyclosporin results in synergistic anti-cancer effects <i>in vitro</i> and <i>in vivo</i>
12:55	<b>Alexander Weng</b> (Berlin, Germany) Mechanistic aspects of the synergistic cytotoxicity between Gypsophila saponins and type I ribosome-inactivating proteins
13:15	Lunch

Friday 03 April 2009	
Afternoon	
<i>Chair: Arthur Frankel</i>	
14:15	<b>Michael G. Rosenblum</b> (Houston, TX, USA) Development of novel, highly cytotoxic fusion constructs containing granzyme B: Unique mechanisms and functions
15:00	<b>Horst Dürkop</b> (Berlin, Germany) ED-B fibronectin: Neoangiogenesis and drug targeting
15:35	<b>Jochen Probst</b> (Tübingen, Germany) Self-adjuvanting messenger RNA-based vaccines as a novel concept in cancer immunotherapy
15:50	<b>Radostina Georgieva</b> (Berlin, Germany) Tumor targeting using magnetite loaded red blood cells
16:05	<b>Stephen H. Leppla</b> (Bethesda, MD, USA) Tumor targeting by protease-activated anthrax toxin proteins
16:40	Concluding remarks ( <i>Christopher Bachran</i> )
17:25	Bus transfer to Potsdamer Platz
18:00	Sunset meeting dinner above the buildings of Berlin (sunset: 19:45)
22:00	Bus transfer to the hotels